Chapter 1022 I Can’t Sit Still Anymore

A Huan Guo mourns. It lasted for nearly half a month. For half a month, the TV shows were basically documentaries that were made before they were broadcast, such as a brief introduction to the life of the elder. From a young age until he became the top leader. The ups and downs of these decades are flashed one by one in more than a dozen episodes of the documentary.

As a person who had a very close relationship with the elder's family, Fan Wubing naturally participated in the memorial activities held later, especially following the leaders of the Politburo and laying a wreath as an important friend.

After handling the matters here, Fan Wubing focused his main energy on negotiating the acquisition case with Haizhou Pharmaceutical Group. After a few months of fading. Fan Wubing and Donghai Province came up with a solution. Bypassing the supervision of central ministries and commissions, the research department of Haizhou Pharmaceutical Group was first separated. Haizhou New Drug Research Institute was established, which was independently controlled by the government. From then on, the research department of Haizhou Pharmaceutical Group was established as a separate branch.

Afterwards, Fan Investment Group reached a cooperation intention with Donghai Province. Fan Investment Group invested 100 million yuan and obtained 80% of the equity of the institute. The new boss of a drug research and development institution built on a skeleton.

Because this case did not rise to the level of direct acquisition of Haizhou Pharmaceutical Group, it bypassed the supervision scope of central ministries and commissions. After the forces that had previously opposed the acquisition of Haizhou Pharmaceutical Group by Fan Investment Group came back to their senses, , only to find that the deal was done, and apart from some criticism of the operating methods, there was no suspicion of violation of regulations, so the main body of Haizhou Pharmaceutical Group remained untouched. What Fan Investment Group acquired was only a small part of the professional institutions that had been carved out by the Donghai Provincial Government.

Moreover, the price of this small-scale acquisition is quite high. After all, the research institute not only has no profitability, but also requires a large amount of money to be invested every year to maintain its operation. It can be said that for the entire Haizhou Pharmaceutical Group, Words are a big burden.

Prior to this, many people from Haizhou Pharmaceutical Group said that the company had so many researchers, but it had never produced any decent research results. On the contrary, the large amount of research expenses and personnel expenditures had overwhelmed Haizhou Pharmaceutical Group. It has been crumbling and overwhelmed, so some people have long wanted to abolish the research department. The company has already made this proposal on our behalf, but the group has never dared to take action. I'm afraid something big will happen.

After all, in the past two years, due to the company's layoffs, many Zhuo sentiments affecting local stability broke out. At this time, from the company leaders to the local leaders, under normal circumstances, they were unwilling to touch the interests of this area.

At this time, Fan Wubing came out; the leaders of Donghai Province, especially the governor Wu Fukuan who was eager to get closer to the Fan family, immediately made a decision. Respecting the previous opinions of Haizhou Pharmaceutical Group, the research department will be independent and follow the path of market-oriented operation. The government and Fan Investment Group will jointly establish a joint-stock research institute, and the benefits generated will be divided between the two according to their equity ratios. .

but,

Fan Investment Group also stated that as Fan continues to inject new funds into the institute, the Donghai Provincial Government’s shareholding ratio in the institute will be diluted accordingly.

, "In other words, if Fan's capital injection exceeds one billion, the Donghai Provincial Government's equity ratio in the institute will be less than 2%?" After Shen Ying learned the news, she asked Fan Wu Ill asked. "It seems that you are determined to win this research department."

"That's natural. Fan Wubing nodded and replied, "In fact, what I really care about is the research team of Haizhou Pharmaceutical Group. After all, this team is still very powerful. It's just limited to the relationship between the system and it has not played its due role. Now that it has been demutualized, I can use it to do many things. "

Fan Wubing has a lot of good things in his hands, such as secret recipes given to him by his teacher Fan Tianlan. These things can be commercialized. Let them become new drugs that are more conducive to promotion, but turning traditional Chinese medicine preparations into tablets, capsules, oral liquids, etc. that meet current market needs requires repositioning. And make some pathological tests and toxicity analysis. Or there are various test requirements that need to meet the requirements of the International Organization for Standardization. Finally, a result is obtained that allows the new drug to be marketed.

All of this requires a professional research team to do, and it cannot be done by the abilities of one or two people.

Fan Wubing wasted no time in researching and promoting new drugs, mainly because he felt the huge pressure from European and American drugs and wanted to carve out a way forward for the domestic drug market and regain many of the traditional drug markets that had been lost.

In recent years, it has been widely believed. In terms of drug research and development capabilities, the United States has eclipsed Europe. However, according to the analysis of all data over the past two decades, in terms of drug innovation, the United States has not surpassed Europe in the efficiency of new drug research and development, and Europe's new drug research and development capabilities are still ahead of the United States. Compared with previously prescribed new drugs. The vast majority of new drugs have no significant increase in clinical efficacy.

Official and industry reports once generally believed that the United States had surpassed Europe in prescribing new drugs. But even though the U.S. Congress and a large number of investors are encouraging pharmaceutical companies to start selling new drugs. These new drugs have no real value and are only slightly more effective than the old drugs.

The United States is developing rapidly in the research and development of global drugs, innovative drugs, biological products and orphan drugs, but Europe's research capabilities have hardly decreased, and Europe is still leading in terms of opening laboratories and global high profits.

It is obvious that the United States has not surpassed Europe in discovering new compounds.

Drug research and development capabilities and total research and development investment are often confused. A very typical propaganda has been since the beginning of two thousand years. The United States has established itself as a major innovator in pharmaceuticals. This statement stems from the fact that the United States has invested more funds in the research sector, but it is still unknown how many genuine new inventions there are in American laboratories.

And many responsible experts say it is untenable to conclude that the vast majority of new drugs are of high quality or important to patients.

From the perspective of patients, doctors and health policy, quality means that new drugs are clinically more effective or have fewer side effects than existing drugs. However, many current investigative reports do not use data or treatment outcomes to evaluate the quality of new drugs. The advertisements of some new drugs have obviously misled consumers, claiming that the new drugs are effective, but judging from the clinical performance of patients taking the drugs. The efficacy of the two is almost

In short, commercial success often does not equate to significant improvements in efficacy.

For now. There is a real need in the country to encourage companies to prescribe new drugs that are more effective than existing drugs. Rather than prescribing a drug that is only slightly better than a placebo. Therefore, some scholars have suggested independent clinical trials sponsored by public institutions such as the National Institutes of Health in the United States. In this way, the advantages and risks of existing treatments can be compared. Publicly sponsored trials can also reduce costs and risks for manufacturers, and improve the research capabilities and competitiveness of small manufacturers by reducing high-cost barriers.

, "Now the government has completely liberalized the approval of new drugs. There are probably no less than 20,000 new drugs released every year, but among them, there are not even 100 that can really be called new drugs. They are all old drugs that have been put on the market under new names after changing their packaging. When Fan Wubing mentioned this issue, he said to Shen Ying, "For example, those drugs that often appear in TV advertisements. In fact, it is an upgraded version of a very simple cold granule, or it is the same thing with a changed packaging method. Not only has the efficacy not improved, but it has also been reduced, but the price is several times or dozens of times higher than the original product. More than times, which is very detrimental to consumers who do not know the truth. "

Fan Wubing is very clear that this situation must be changed in view of the current problems of insufficient attention, insufficient investment, and failure to keep up with basic research on domestic innovative drug research companies. Relying on the government is not enough. We have no choice but to do something ourselves.

In order to rank among the world's advanced leaders in the research and production of innovative drugs, we must first cultivate a group of outstanding talents. These include excellent technical talents and management talents. Therefore, what should be solved first is the incentive mechanism for scientific researchers engaged in application foundation and development, and exploring options and equity issues for scientists when intangible assets are invested in shares. This mainly includes scientific researchers from scientific research institutes and enterprises.

After all, the research and development of innovative drugs will eventually become commonplace. In addition to needing excellent technical talents, we must also cultivate an excellent team of management talents.

In addition to solving the problem of talent, it is also necessary to strengthen basic research and lay a solid foundation for the successful development of innovative drugs. The governments of almost all developed countries allocate major funds to support basic research, while funds for applied basic and development research are mainly invested by enterprises, and the same is true for the research and development of innovative drugs.

However, due to many domestic reasons such as systems and mechanisms, it is difficult for the currently dominant state-owned and state-controlled enterprises to become innovation entities. In general. At present, such companies still lack the ability to spend huge sums of money on original innovative drug research.

So at this stage. It is necessary to promote the achievements accumulated by various research institutes over the years to industrialization as soon as possible and to set up some major industrialization projects to support it. With the widespread and effective establishment of modern enterprise systems. As the investment strength of a group of enterprises increases, it is inevitable that enterprises will become the main body of scientific and technological innovation.

Now Fan Wubing is just taking this path ahead of time, so as to strengthen the research and development of domestic innovative drugs as soon as possible, so as not to lag too far behind his foreign counterparts.

New technologies have become the starting point and an indispensable part of new drug research. Tracking cutting-edge key technologies is very important for the research and development of new drugs. Based on the latest results of the human genome, it integrates high and new technologies in drug research such as molecular biology, structural biology, computer-aided virtual screening, combinatorial chemistry and high-throughput screening. It is a good idea to establish a platform for innovative drug discovery and practice in a variety of target protein systems related to important diseases.

New drug research is actually a systematic project that guides the establishment of a high-tech platform for the centralized creation of new drugs and the formation of a research group composed of high-level interdisciplinary researchers to improve the innovative drug research system while strengthening the construction of key bottleneck technology platforms. Such as preparation technology, drug distribution platform, etc. These are not problems that current state-owned enterprises can solve.

But what happened next was a bit ridiculous. After seeing that Fan Investment Group seemed to have little interest in acquiring Haizhou Pharmaceutical Group, the cadres and employees of Haizhou Pharmaceutical Group were very disappointed. After all, everyone knows the current situation of Haizhou Pharmaceutical Group. If it does not introduce strategic investors, it may not be able to survive soon.

The so-called annual sales of over 10 billion is just talk. At this time, the group's profits have been declining. The debt ratio has been rising. If there is no breakthrough, everyone will have to go to the northwest wind next year.

When Fan's Investment Group had the intention to acquire it before, the employees of Haizhou Pharmaceutical Group were very willing to do so, because everyone knew that the living standards of employees of the major companies acquired by Fan are now in an advantageous position in the local area. If Haizhou Pharmaceutical Group is successfully acquired by Fan, it will be no exception.

But no one expected that the acquisition case was stopped by the central ministries and commissions, and everyone's thoughts turned into bubbles. It is really unacceptable. Seeing that the group's most unpopular research department was separated, many people were happy, thinking that they finally got rid of a big burden.

But Fan's Investment Group actually acquired the independent Haizhou New Drug Research Institute, which was surprising again. Compared with the new drug research institute that requires a lot of investment and support funds, the production enterprise is a part that can directly generate income? !

Fan's ideas. It is always unpredictable.

However, after confirming through internal relations that Fan was no longer interested in the acquisition of Haizhou Pharmaceutical Group, most of the employees of Haizhou Pharmaceutical Group felt a little angry, thinking that the inaction of the central ministries and commissions had increased the risks they faced. If Haizhou Pharmaceutical Group went bankrupt next year, wouldn't they all be laid off?

The leaders could get out in advance and work in other places, but what other ways could they live? As professional technical workers, they are actually the lowest level of this society. What kind of job can they find if they leave the company they can work for?

Therefore, the employees of Haizhou Pharmaceutical Group organized a petition team of up to 200 people and went directly to Beijing, of course. The banner they put out was a tour group. "(To be continued)